KNTE(Delisted)
KinnateยทNASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About KNTE
Kinnate Biopharma Inc.
A clinical-stage precision oncology company focused on expanding on the promise of targeted therapies for those battling cancer
103 Montgomery Street
, Suite 150
, The Presidio of San Francisco
, San Francisco
, CA 94129
--
Kinnate Biopharma Inc., incorporated in Delaware. The company is a clinical-stage precision oncology company focused on discovering, designing and developing small molecule kinase inhibitors for difficult-to-treat, genome-defined cancers.
Company Financials
EPS
KNTE has released its 2023 Q3 earnings. EPS was reported at -0.65, versus the expected -0.67, beating expectations. The chart below visualizes how KNTE has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
No Data
You can ask Aime
No Data
